Abstract
Objective: We report a case of neuroleptic malignant syndrome in a woman who assumed risperidone for schizoaffective disorders. Case Summary: A 45-year-old woman affected by schizoaffective disorders was admitted to Infectious Disease unit of Crotone Hospital because of a diagnosis of a fever of unknown origin. Clinical evaluation documented confusion and dysphoria, whereas chemical blood evaluation revealed acidosis and liver dysfunction. After few days she was transferred to the Operative Unit of Internal Medicine of San Giovanni in Fiore Hospital because of an increase in liver transaminases. Clinical evaluation showed the persistence of fever (38.8 degrees Celsius), with an increase in CPK, and liver enzymes. Pharmacological evaluation indicated a probable relationship between risperidone and NMS and led to a diagnosis of neuroleptic malignant syndrome associated with risperidone in a woman with schizophrenia. About seven days later, we recorded a complete resolution of her psychiatric symptoms. Discussion: We postulate a possible interaction between risperidone and neuroleptic malignant syndrome and we suggest to use risperidone with caution in both young and middle aged people.
Keywords: Risperidone, neuroleptic malignant syndrome, schizophrenic woman
Current Drug Safety
Title: A Case of Neuroleptic Malignant Syndrome Induced by Risperidone in a Schizophrenic Woman
Volume: 4 Issue: 2
Author(s): Luca Gallelli, Vincenzo Spagnuolo, Caterina Palleria, Giovambattista De Sarro and Maria Ferraro
Affiliation:
Keywords: Risperidone, neuroleptic malignant syndrome, schizophrenic woman
Abstract: Objective: We report a case of neuroleptic malignant syndrome in a woman who assumed risperidone for schizoaffective disorders. Case Summary: A 45-year-old woman affected by schizoaffective disorders was admitted to Infectious Disease unit of Crotone Hospital because of a diagnosis of a fever of unknown origin. Clinical evaluation documented confusion and dysphoria, whereas chemical blood evaluation revealed acidosis and liver dysfunction. After few days she was transferred to the Operative Unit of Internal Medicine of San Giovanni in Fiore Hospital because of an increase in liver transaminases. Clinical evaluation showed the persistence of fever (38.8 degrees Celsius), with an increase in CPK, and liver enzymes. Pharmacological evaluation indicated a probable relationship between risperidone and NMS and led to a diagnosis of neuroleptic malignant syndrome associated with risperidone in a woman with schizophrenia. About seven days later, we recorded a complete resolution of her psychiatric symptoms. Discussion: We postulate a possible interaction between risperidone and neuroleptic malignant syndrome and we suggest to use risperidone with caution in both young and middle aged people.
Export Options
About this article
Cite this article as:
Gallelli Luca, Spagnuolo Vincenzo, Palleria Caterina, De Sarro Giovambattista and Ferraro Maria, A Case of Neuroleptic Malignant Syndrome Induced by Risperidone in a Schizophrenic Woman, Current Drug Safety 2009; 4 (2) . https://dx.doi.org/10.2174/157488609788173062
DOI https://dx.doi.org/10.2174/157488609788173062 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Weight Loss in Older Persons: New Therapeutic Approaches
Current Pharmaceutical Design Microenvironmental Determinants of Adult Neural Stem Cell Proliferation and Lineage Commitment in the Healthy and Injured Central Nervous System
Current Stem Cell Research & Therapy Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews Extracts and Flavonoids of <i>Passiflora</i> Species as Promising Anti-inflammatory and Antioxidant Substances
Current Pharmaceutical Design Clozapine Safety, 35 Years Later
Current Drug Safety Proteome Adjustments Post Gradual Hypoxic Stress in Barilius bendelisis: Insights into Adaptive Strategies of a Hill Stream Cyprinid
Current Proteomics Pharmacological Inhibition of Protein Tyrosine Phosphatase 1B: A Promising Strategy for the Treatment of Obesity and Type 2 Diabetes Mellitus
Current Medicinal Chemistry Early Life Programming of Obesity: The Impact of the Perinatal Environment on the Development of Obesity and Metabolic Dysfunction in the Offspring.
Current Diabetes Reviews ACE Inhibitor-Angiotensin Receptor Blocker Combinations: A Clinicians Perspective
Mini-Reviews in Medicinal Chemistry Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology Structure and Inhibitor Binding Mechanisms of 11β -Hydroxysteroid Dehydrogenase Type 1
Current Chemical Biology Polypeptide Delivery Across The Blood-Brain Barrier
Current Drug Targets - CNS & Neurological Disorders Prevalence of Neuropsychiatric Symptoms in Alzheimers Disease and Vascular Dementia
Current Alzheimer Research Control of Menopausal Transition through Physical Exercises
Current Women`s Health Reviews Pharmacological Therapy of Cushings Syndrome: Drugs and Indications
Mini-Reviews in Medicinal Chemistry Drug Targeting in Bronchial Asthma: Inhaled Corticosteroids Should Reach the Peripheral Airways
Current Drug Therapy Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Endocannabinoids in Neuroimmunology and Stress
Current Drug Targets - CNS & Neurological Disorders Inflammation as Therapeutic Objective in Stroke
Current Pharmaceutical Design An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets